companies

Zetta Genomics Seed

Founded 2018
Employees 20+
Primary contact
50/60 Station Road
C/O HCR Hewitsons
CB1 2JH Cambridge
United Kingdom
+44 7779 663045
Links
https://zettagenomics.com/
Sections
Technologies
University of Cambridge technology spin-out Zetta Genomics is a leader in large-scale genomic data management for precision medicine. It is employing big data technology and best practice security to leverage genomic data benefits while preserving data privacy. The company's flagship offering, the XetaBase platform, is a genomic data management technology that powers the discovery and delivery of precision medicine at scale. It was built on the open-source OpenCB platform, co-developed by Zetta's founder Ignacio Medina to allow researchers and clinicians to securely store, easily access and dynamically interrogate vast and increasing volumes of genomic data - on demand. The technology brings genome-enabled discovery, healthcare analytics and population research into the lab - and prognostics, diagnostics and therapeutics into the clinic.
Select partners: Sano, University of Cambridge, Microsoft, Genomics England, mongoDB.
Founded 2018
Employees 20+
Primary contact
50/60 Station Road
C/O HCR Hewitsons
CB1 2JH Cambridge
United Kingdom
+44 7779 663045
Links
https://zettagenomics.com/
Sections
Technologies

Funding 💰

Total £5.65M
Last round 🔗 £1.9M
Second Seed
April 18, 2023.
Select investors Nina Capital, APEX Ventures, University of Cambridge Enterprise, Parkwalk Advisors, Innovate UK

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Solving the real problem: Legacy IT cannot scale to meet the exacting demands of genomic data at scale. Zetta's technology saves the valuable time of bioinformaticians and enables safe and convenient access to the large amounts of complex data they need to conduct the lab's life-changing research.
  • Riding the rising wave: Genomic medicine has been on the roll in recent years, and Zetta Genomics has "what it takes" to benefit from the growth of this market, with its offering targeting multiple sectors - including genomic healthcare, biomedical research and pharmaceutical R&D.
  • Leadership team with a solid track-record: CEO Will Spooner previously co-founded Eagle Genomics, has been a board member for ten years, and was head of innovation at Genomics England. Chair, Ludo Chapman, has led businesses through virtually every stage of growth, from driving successful start-ups to revitalising established companies.

In the news 📰

Zetta Genomics gets £1.9M in second round seed funding
April 19, 2023

Quotes 💬

“
Genomic medicine has enjoyed explosive growth in the past five years, but this is set to be eclipsed in the next decade. XetaBase is an enabling technology - empowering virtually every research field and clinical application. As genomic sequencing moves from the hundreds of thousands to the hundreds of millions, Nina Capital is confident that Zetta Genomics' growth will both drive and be driven by rapid advances in precision medicine.
— Marc Subirats, Partner at Nina Capital 🔗
“
From our first meeting it was clear that Ignacio [Founder & CTO] had developed something incredibly special. Zetta's technology helps researchers and clinicians fully exploit genomic data, speeding the delivery of precision medicine across the world.
— Dr Elaine Loukes, Investment Director at University of Cambridge Enterprise 🔗
Last update: April 21, 2023